Innate Pharma Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Innate Pharma han disminuido a una tasa media anual de -18.6%, mientras que en la industria Biotechs los beneficios crecieron en un 17.4% anualmente. Los ingresos han ido disminuyendo a una tasa media de 23% al año.
Información clave
-18.60%
Tasa de crecimiento de los beneficios
-17.00%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 30.80% |
| Tasa de crecimiento de los ingresos | -22.98% |
| Rentabilidad financiera | n/a |
| Margen neto | -546.11% |
| Próxima actualización de resultados | 17 Sep 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Mar 29
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Nov 17Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
Jul 19
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Apr 02Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Feb 22Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09Desglose de ingresos y gastos
Cómo gana y gasta dinero Innate Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 9 | -49 | 19 | 0 |
| 30 Sep 25 | 11 | -48 | 20 | 0 |
| 30 Jun 25 | 13 | -46 | 20 | 0 |
| 31 Mar 25 | 16 | -48 | 20 | 0 |
| 31 Dec 24 | 20 | -49 | 20 | 0 |
| 30 Sep 24 | 27 | -42 | 19 | 0 |
| 30 Jun 24 | 34 | -34 | 19 | 0 |
| 31 Mar 24 | 48 | -21 | 19 | 0 |
| 31 Dec 23 | 62 | -8 | 18 | 0 |
| 30 Sep 23 | 57 | -35 | 19 | 0 |
| 30 Jun 23 | 52 | -63 | 19 | 0 |
| 31 Mar 23 | 55 | -60 | 21 | 0 |
| 31 Dec 22 | 58 | -58 | 22 | 0 |
| 30 Sep 22 | 57 | -40 | 24 | 0 |
| 30 Jun 22 | 57 | -22 | 25 | 0 |
| 31 Mar 22 | 41 | -34 | 25 | 0 |
| 31 Dec 21 | 25 | -45 | 26 | 0 |
| 30 Jun 21 | 46 | -8 | 17 | 0 |
| 31 Mar 21 | 58 | -4 | 18 | 0 |
| 31 Dec 20 | 70 | -1 | 19 | 0 |
| 30 Sep 20 | 67 | -54 | 31 | 0 |
| 30 Jun 20 | 63 | -44 | 31 | 0 |
| 31 Mar 20 | 75 | -33 | 28 | 0 |
| 31 Dec 19 | 85 | 8 | 21 | 0 |
| 30 Sep 19 | 108 | 5 | 24 | 0 |
| 30 Jun 19 | 130 | 31 | 22 | 0 |
| 31 Mar 19 | 112 | 17 | 20 | 0 |
| 31 Dec 18 | 94 | 3 | 18 | 0 |
| 30 Sep 18 | 70 | -19 | 16 | 0 |
| 30 Jun 18 | 46 | -40 | 15 | 0 |
| 31 Mar 18 | 45 | -44 | 16 | 0 |
| 31 Dec 17 | 44 | -48 | 17 | 0 |
| 30 Sep 17 | 55 | -28 | 16 | 0 |
| 30 Jun 17 | 66 | -8 | 14 | 0 |
| 31 Mar 17 | 66 | 3 | 12 | 0 |
| 31 Dec 16 | 66 | 13 | 10 | 0 |
| 30 Sep 16 | 53 | 5 | 8 | 0 |
| 30 Jun 16 | 41 | -2 | 7 | 0 |
| 31 Mar 16 | 33 | -4 | 6 | 0 |
| 31 Dec 15 | 25 | -7 | 6 | 0 |
| 30 Sep 15 | 17 | -13 | 5 | 0 |
| 30 Jun 15 | 8 | -19 | 4 | 0 |
Ingresos de calidad: IPH actualmente no es rentable.
Margen de beneficios creciente: IPH actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: IPH no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 18.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IPH en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: IPH no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (45%).
Rentabilidad financiera
Alta ROE: El pasivo de IPH supera su activo, por lo que es difícil calcular su rentabilidad financiera.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/04/30 19:42 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Innate Pharma S.A. está cubierta por 13 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |